XOMA adds to its royalty and milestone portfolio with Ixinity deal

Adding to a string of such deals, US biotech XOMA Corporation (Nasdaq: XOMA) has now acquired the commercial payment and a portion of the milestone rights to Ixinity [coagulation factor IX (recombinant)], which is marketed by Canada’s Medexus Pharmaceuticals (TSE: MDP) for the control and prevention of bleeding episodes and postoperative management in people with hemophilia B, from Aptevo Therapeutics (Nasdaq: APVO).

Market reaction was mixed, with Medexus’ shares leaping 15.7% to C$1.55, while XOMA dipped 1.7% and Aptevo rose 1%.

“Adding a new commercial payment stream will benefit XOMA’s shareholders as we build our base of consistent incoming cash flows to help accelerate our royalty aggregation strategy,” stated Brad Sitko, chief investment officer at XOMA. “Ixinity has an established niche in the hemophilia B treatment paradigm, with near-term potential opportunities for growth, including label and geographic expansion.”